The earnings call presented a positive outlook with significant progress in regulatory approvals, commercial launch preparations, and pipeline development. Financial health remains strong despite increased operating expenses. However, challenges in achieving immediate launch uptake were noted.

Company Guidance

During the Crinetics Pharmaceuticals Second Quarter 2025 Financial Results Conference Call, the company provided guidance on several key metrics and strategic initiatives. They reported a strong financial position with $1.2 billion in cash, cash equivalents, and investments, and a net cash usage of $77.8 million for the quarter. The company's research and development expenses were $80.3 million, while selling, general, and administrative expenses reached $49.8 million. Crinetics is anticipating the approval of its paltusotine NDA in September 2025 and has prepared for the launch of PALSONIFY, with a commercial team and approximately 30 sales representatives. They project a gradual adoption rate for PALSONIFY due to the infrequent visits of acromegaly patients to endocrinologists. The market research indicates that about 500 newly diagnosed patients per year and 11,000 currently diagnosed patients could be candidates for PALSONIFY, along with potentially 17,000 undiagnosed patients. Furthermore, the company has ongoing regulatory processes for other pipeline products, including atumelnant for congenital adrenal hyperplasia and CRN09682 for SST2 expressing solid tumors, with several pivotal programs set to initiate soon. Crinetics has also adjusted its cash usage guidance for 2025, now estimating $340 million to $370 million, down from the previous upper limit of $380 million, and plans to use its existing cash to fund operations into 2029.

FDA Approval Progress for Paltusotine

The NDA review for paltusotine remains on track, with anticipated FDA approval expected in September 2025. The regulatory team has maintained excellent momentum, and the launch team has been assembled in preparation for the anticipated approval.

Commercial Launch Strategy for PALSONIFY

Crinetics has made meaningful progress in interactions with healthcare professionals, patients, and payers as they approach the launch of PALSONIFY. They have built out a commercial team and are onboarding a sales force to support the launch.

Pipeline Progress and Multiple Clinical Trials

Crinetics is advancing several clinical programs, including trials for carcinoid syndrome and congenital adrenal hyperplasia. They also plan to initiate a Phase II/III study for ACTH dependent Cushing's syndrome in 2026.

Strong Financial Position

Crinetics ended the quarter with $1.2 billion in cash, cash equivalents, and investments, with sufficient funds to operate into 2029. They have lowered the high end of their guidance for net cash used in operations for 2025.

Crinetics Pharmaceuticals (CRNX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRNX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-1.23 / -	-0.96	―	―	―
Aug 07, 2025	2025 (Q2)	-1.08 / -1.23	-0.94	-30.85% (-0.29)	―
May 08, 2025	2025 (Q1)	-0.94 / -1.04	-0.93	-11.83% (-0.11)	―
Feb 27, 2025	2024 (Q4)	-0.89 / -0.88	-0.9	2.22% (+0.02)	―
Nov 12, 2024	2024 (Q3)	-0.91 / -0.96	-1.01	4.95% (+0.05)	―
Aug 08, 2024	2024 (Q2)	-0.86 / -0.94	-0.94	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.81 / -0.93	-0.85	-9.41% (-0.08)	―
Feb 28, 2024	2023 (Q4)	-0.86 / -0.90	-0.84	-7.14% (-0.06)	―
Nov 07, 2023	2023 (Q3)	-0.87 / -1.01	-0.78	-29.49% (-0.23)	―	―
Aug 08, 2023	2023 (Q2)	-0.87 / -0.94	-0.81	-16.05% (-0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRNX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$27.88	$26.85	-3.69%
May 08, 2025	$32.70	$30.68	-6.18%
Feb 27, 2025	$33.21	$35.78	+7.74%
Nov 12, 2024	$58.78	$58.92	+0.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Crinetics Pharma (CRNX) report earnings?

Crinetics Pharma (CRNX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Crinetics Pharma (CRNX) earnings time?

Crinetics Pharma (CRNX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRNX EPS forecast?

CRNX EPS forecast for the fiscal quarter 2025 (Q3) is -1.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing